NR 566 Final Exam 2026/2027 – 100+ Questions & Answers | STIs, Reproductive Pharmacology, Migraines, Parkinson’s & Psych Meds

This NR 566 Final Exam 2026/2027 study document provides 100+ exam questions, correct answers, medication regimens, patient-teaching points, and pharmacology concepts across 16 pages. Major topics include sexually transmitted infections (STIs), reproductive and genitourinary pharmacology, contraception and hormone therapy, migraine medications, Alzheimer’s disease and dementia therapy, Parkinson’s disease medications, anxiety and depression pharmacotherapy, bipolar medications, antipsychotics, insomnia treatment, and complementary or alternative therapies. The uploaded document identifies the course as NR 566 and the academic year as 2026/2027, but it does not identify a university; therefore, the institution is listed as University Not Specified rather than attributing it to an unsupported school. NR 566 Final 2026 The opening section provides concentrated review of STI and genitourinary pharmacology. The source includes drug, dose, route, and frequency questions for chlamydia, uncomplicated gonococcal urethritis, bacterial vaginosis, genital herpes (HSV), trichomoniasis, and syphilis. Medications appearing in these questions include azithromycin, doxycycline, ceftriaxone, metronidazole, clindamycin, acyclovir, famciclovir, valacyclovir, tinidazole, and benzathine penicillin G. Because antimicrobial recommendations can change as resistance patterns and clinical guidelines are updated, the specific regimens reproduced in this study guide should be checked against current clinical guidance rather than treated as current prescribing instructions. NR 566 Final 2026 The document also reviews benign prostatic hyperplasia and reproductive pharmacology. BPH medications include doxazosin, dutasteride, and terazosin, with questions on hypotension, dizziness, urinary-flow improvement, delayed therapeutic response, sexual adverse effects, and patient education. Reproductive-health material covers estrogen routes, progestins, medroxyprogesterone acetate, testosterone therapy, etonogestrel implants, and interactions involving carbamazepine and hormonal contraception. Erectile-dysfunction therapy includes alprostadil and intracavernosal papaverine/phentolamine, with administration and adverse-effect teaching. NR 566 Final 2026 A significant section addresses migraine pharmacology and prevention. The source distinguishes preventive from abortive therapy and discusses beta blockers such as propranolol and metoprolol, divalproex, amitriptyline, NSAIDs, triptans, and butorphanol. Students review when preventive treatment may be considered, the mechanism of sumatriptan, cardiovascular considerations associated with triptans, and the importance of early treatment during an acute migraine attack. Feverfew later appears in the complementary-therapy section as a migraine-prophylaxis topic. NR 566 Final 2026 The neurocognitive and Parkinson’s disease sections review rivastigmine, donepezil, memantine, pramipexole, bromocriptine, levodopa/carbidopa, and COMT inhibitors. High-yield concepts include rivastigmine patch administration, titration of donepezil, cholinesterase-inhibitor adverse effects, renal considerations with memantine, dopamine-agonist adverse effects, sleep attacks, and the use of COMT inhibitors alongside levodopa. The review also discusses levodopa/carbidopa response and the “wearing-off” or fluctuating motor-control concepts associated with Parkinson’s pharmacotherapy. NR 566 Final 2026 Another major area is psychiatric pharmacology. Anxiety content covers panic disorder and generalized anxiety disorder, with benzodiazepines, SSRIs, SNRIs, buspirone, alprazolam, clonazepam, fluoxetine, paroxetine, sertraline, duloxetine, venlafaxine, diazepam, lorazepam, and related medications appearing throughout the source. Depression review addresses expected antidepressant response, treatment changes when an initial medication is ineffective, suicide-risk warnings, SSRI adverse effects and interactions, SNRI concepts, tricyclic antidepressants, and MAOI dietary education. NR 566 Final 2026 The document further reviews bipolar disorder and antipsychotic medication safety, particularly lithium therapeutic concentrations, lithium interactions, and first-generation antipsychotic adverse reactions. The source highlights extrapyramidal symptoms, tardive dyskinesia, acute dystonia, parkinsonism, akathisia, neuroleptic malignant syndrome, anticholinergic effects, orthostatic hypotension, seizure considerations, endocrine effects, and sexual dysfunction. It also emphasizes avoiding SSRI–MAOI combinations because of serotonin-syndrome risk. NR 566 Final 2026 The sleep pharmacology section covers benzodiazepines such as triazolam and flurazepam, benzodiazepine-like hypnotics including zolpidem, eszopiclone, and zaleplon, the melatonin-receptor agonist ramelteon, and suvorexant. Questions distinguish medications intended primarily to help with sleep initiation and review medication classes commonly encountered in insomnia pharmacotherapy. NR 566 Final 2026 The final section expands the exam review into herbal products, dietary supplements, and complementary therapies. Topics include kava, ginkgo biloba, St. John’s wort, ginger root, echinacea, flaxseed, coenzyme Q10, and feverfew, with attention to adverse effects, contraindications, interactions, and patient education. The material also covers the Dietary Supplement Health and Education Act (DSHEA) of 1994, the Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006, and current good manufacturing practice concepts for supplements. NR 566 Final 2026 Relevant students: This material is particularly relevant for NR 566 students, Family Nurse Practitioner students, Adult-Gerontology Nurse Practitioner students, PMHNP students completing advanced pharmacology, MSN and DNP students, APRN students, and graduate nursing students preparing for pharmacology finals. It is especially useful for learners reviewing STI treatment, reproductive pharmacology, BPH, hormone therapy, contraception, migraines, Parkinson’s disease, Alzheimer’s medications, antidepressants, anxiolytics, antipsychotics, sleep medications, and complementary therapies. Academic references: For deeper study and verification, students can cross-reference medication concepts with Lehne’s Pharmacology for Nursing Care and current FDA prescribing information. STI treatment regimens should be verified against current CDC guidance, while psychiatric and neurological pharmacotherapy should be checked against current professional guidelines and medication labeling. These are supplementary references; the uploaded NR 566 document does not identify a specific textbook, journal, or guideline as the original source of its questions. Keywords: NR 566 Final Exam, NR 566 Final 2026, NR 566 Final 2027, NR 566 questions and answers, NR 566 study guide, NR 566 pharmacology, advanced pharmacology final exam, FNP pharmacology exam, nurse practitioner pharmacology, STI pharmacology, chlamydia treatment, gonorrhea treatment, bacterial vaginosis treatment, genital herpes treatment, trichomoniasis treatment, syphilis treatment, reproductive pharmacology, BPH medications, doxazosin, dutasteride, terazosin, estrogen therapy, progestin therapy, testosterone therapy, Nexplanon, erectile dysfunction medications, alprostadil, migraine pharmacology, migraine prevention, sumatriptan, triptans, Parkinson disease medications, levodopa carbidopa, pramipexole, COMT inhibitors, Alzheimer medications, rivastigmine, donepezil, memantine, anxiety pharmacology, panic disorder medications, GAD medications, antidepressants, SSRIs, SNRIs, tricyclic antidepressants, MAOIs, lithium, antipsychotics, extrapyramidal symptoms, insomnia medications, zolpidem, ramelteon, herbal supplements, St Johns wort, ginkgo biloba, echinacea, feverfew, DSHEA, APRN pharmacology, graduate nursing exam